The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Cancer biologics Market Expected To Scale Between 2026 And 2030?
The cancer biologics market has demonstrated significant growth in recent years. It is projected to increase from $129.05 billion in 2025 to $140.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical expansion can be attributed to factors like the rising global prevalence of cancer, increasing demand for advanced cancer therapies, heightened oncology research activities, the limited efficacy of conventional chemotherapy, and the expansion of hospital-based cancer treatment centers.
The cancer biologics market size is expected to undergo significant growth over the next few years, projected to reach $203.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This expansion during the forecast period is primarily attributed to advancements in cell and gene therapy platforms, an increase in approvals for novel biologics, the growth of personalized oncology treatments, rising investment in cancer biologics research and development, and the expansion of biologics manufacturing capacity. Major trends expected in this period include the increasing adoption of immunotherapy and targeted biologic treatments, a greater utilization of monoclonal antibodies in oncology, the growth of cell and gene therapy-based cancer treatments, the expansion of cancer vaccine development programs, and a heightened focus on combination biologic therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp
What Key Factors Are Shaping The Cancer biologics Market Landscape?
The increasing occurrence of chronic diseases is a primary catalyst fueling the expansion of the cancer biologics market. These long-lasting health conditions, which impair individuals’ well-being, include cancer as one of the most widespread. The most frequently observed cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, in February 2024, data released by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, revealed that a growing number of Americans are managing several chronic conditions, with 42% experiencing two or more, and 12% contending with five or more. Therefore, the escalating prevalence of chronic diseases is anticipated to drive the cancer biologics market’s growth in the coming years.
Which Segment Classifications Are Used In The Cancer biologics Market Segment Analysis?
The cancer biologics market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types
2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications
3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines
3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy
4) By Other Types: Cytokines, Growth Factors, Fusion Proteins
What Emerging Trends Are Seen In The Cancer biologics Market?
Leading companies in the cancer biologics market are dedicated to developing novel treatments like bispecific antibodies and biomarker guided biologics, aiming to boost treatment effectiveness and more precisely target specific cancer cells. Bispecific antibodies represent an advanced biologic therapy designed to simultaneously attach to two distinct epitopes or targets, while biomarker guided biologics are crafted to specifically attack tumor cells identified by particular molecular markers. For example, in November 2024, the U.S. Food & Drug Administration (FDA) granted accelerated approval to Ziihera (zanidatamab hrii) for adults suffering from previously treated, unresectable, or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC), as reported by the Dublin-based global biopharmaceutical company, Jazz Pharmaceuticals Public Limited Company. This approval establishes Ziihera as the first and only dual HER2 targeted bispecific antibody for this indication, thereby extending the utility of HER2 targeted biologic therapy into a new tumor type beyond conventional uses.
Which Firms Are Contributing To The Cancer biologics Market Ecosystem?
Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.
Get The Full Cancer biologics Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Which Region Has The Greatest Market Share In The Cancer biologics Market?
North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cancer biologics Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company
Point Of Care Diagnostics Devices And Equipment Market Report 2026
Cell Culture Consumables And Equipment Market Report 2026
Metabolomics Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model